ATE415421T1 - Deamidiertes interferon-beta - Google Patents
Deamidiertes interferon-betaInfo
- Publication number
- ATE415421T1 ATE415421T1 AT05818235T AT05818235T ATE415421T1 AT E415421 T1 ATE415421 T1 AT E415421T1 AT 05818235 T AT05818235 T AT 05818235T AT 05818235 T AT05818235 T AT 05818235T AT E415421 T1 ATE415421 T1 AT E415421T1
- Authority
- AT
- Austria
- Prior art keywords
- deamidated
- beta
- interferon
- interferon beta
- native
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title abstract 3
- 108090000467 Interferon-beta Proteins 0.000 title abstract 3
- 229960001388 interferon-beta Drugs 0.000 title abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000029983 protein stabilization Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 238000012113 quantitative test Methods 0.000 abstract 1
- 238000004007 reversed phase HPLC Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62683704P | 2004-11-10 | 2004-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE415421T1 true ATE415421T1 (de) | 2008-12-15 |
Family
ID=36337216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05818235T ATE415421T1 (de) | 2004-11-10 | 2005-11-10 | Deamidiertes interferon-beta |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7595040B2 (enExample) |
| EP (1) | EP1809662B1 (enExample) |
| JP (1) | JP4891250B2 (enExample) |
| KR (1) | KR101330626B1 (enExample) |
| CN (1) | CN101056890B (enExample) |
| AT (1) | ATE415421T1 (enExample) |
| AU (1) | AU2005304486B2 (enExample) |
| BR (1) | BRPI0517697A (enExample) |
| CA (1) | CA2587061C (enExample) |
| DE (1) | DE602005011321D1 (enExample) |
| ES (1) | ES2318575T3 (enExample) |
| MX (1) | MX2007004990A (enExample) |
| PL (1) | PL1809662T3 (enExample) |
| PT (1) | PT1809662E (enExample) |
| RU (1) | RU2404190C2 (enExample) |
| WO (1) | WO2006053134A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| EP2059528A2 (en) * | 2006-08-08 | 2009-05-20 | Novartis Ag | Recombinant interferon-beta with enhanced biological activity |
| WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| WO2009045553A1 (en) * | 2007-10-05 | 2009-04-09 | Barofold, Inc. | High pressure treatment of aggregated interferons |
| WO2015150468A2 (en) * | 2014-04-04 | 2015-10-08 | Ares Trading S.A. | Novel ifn beta protein analogs |
| RU2739261C1 (ru) * | 2019-12-31 | 2020-12-22 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Способ количественного определения антипролиферативной активности интерферона-бета человека |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
| US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
| TR199901968T2 (xx) | 1996-12-24 | 1999-12-21 | Biogen, Inc. | Sabit s�v� interferon form�lleri. |
| US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| CA2304808C (en) * | 1997-09-23 | 2011-03-22 | Michael Tschope | Liquid interferon-.beta. formulations |
| DE60045247D1 (de) | 1999-07-28 | 2010-12-30 | Genentech Inc | Zusammensetzungen und verfahren zur behandlung von tumoren |
| ES2180416B1 (es) | 2001-03-12 | 2004-06-01 | BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. | Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen. |
| AR034749A1 (es) * | 2001-07-09 | 2004-03-17 | Schering Ag | Formulaciones de interferon beta humano |
| RU2216345C1 (ru) * | 2002-03-21 | 2003-11-20 | Закрытое Акционерное Общество "Биокад" | Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием |
| KR100541850B1 (ko) * | 2003-03-31 | 2006-01-11 | 삼성정밀화학 주식회사 | 인간 인터페론-베타 변이체 및 그의 제조방법 |
-
2005
- 2005-11-10 AU AU2005304486A patent/AU2005304486B2/en not_active Ceased
- 2005-11-10 BR BRPI0517697-2A patent/BRPI0517697A/pt not_active IP Right Cessation
- 2005-11-10 EP EP05818235A patent/EP1809662B1/en not_active Expired - Lifetime
- 2005-11-10 WO PCT/US2005/040758 patent/WO2006053134A2/en not_active Ceased
- 2005-11-10 MX MX2007004990A patent/MX2007004990A/es active IP Right Grant
- 2005-11-10 RU RU2007121515/04A patent/RU2404190C2/ru not_active IP Right Cessation
- 2005-11-10 CA CA2587061A patent/CA2587061C/en not_active Expired - Fee Related
- 2005-11-10 AT AT05818235T patent/ATE415421T1/de active
- 2005-11-10 CN CN2005800381182A patent/CN101056890B/zh not_active Expired - Fee Related
- 2005-11-10 DE DE602005011321T patent/DE602005011321D1/de not_active Expired - Lifetime
- 2005-11-10 PT PT05818235T patent/PT1809662E/pt unknown
- 2005-11-10 JP JP2007540208A patent/JP4891250B2/ja not_active Expired - Fee Related
- 2005-11-10 PL PL05818235T patent/PL1809662T3/pl unknown
- 2005-11-10 ES ES05818235T patent/ES2318575T3/es not_active Expired - Lifetime
- 2005-11-10 US US11/271,516 patent/US7595040B2/en not_active Expired - Fee Related
- 2005-11-10 KR KR1020077011869A patent/KR101330626B1/ko not_active Expired - Fee Related
-
2009
- 2009-03-25 US US12/410,540 patent/US20090263355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0517697A (pt) | 2008-10-14 |
| CN101056890B (zh) | 2012-05-09 |
| PT1809662E (pt) | 2009-02-26 |
| WO2006053134A3 (en) | 2006-08-31 |
| CA2587061C (en) | 2011-08-16 |
| US7595040B2 (en) | 2009-09-29 |
| PL1809662T3 (pl) | 2009-07-31 |
| KR101330626B1 (ko) | 2013-11-18 |
| JP4891250B2 (ja) | 2012-03-07 |
| US20090263355A1 (en) | 2009-10-22 |
| AU2005304486B2 (en) | 2011-08-11 |
| DE602005011321D1 (de) | 2009-01-08 |
| CA2587061A1 (en) | 2006-05-18 |
| US20060120998A1 (en) | 2006-06-08 |
| JP2008519769A (ja) | 2008-06-12 |
| RU2007121515A (ru) | 2008-12-20 |
| AU2005304486A1 (en) | 2006-05-18 |
| MX2007004990A (es) | 2007-06-14 |
| EP1809662A2 (en) | 2007-07-25 |
| WO2006053134A2 (en) | 2006-05-18 |
| RU2404190C2 (ru) | 2010-11-20 |
| ES2318575T3 (es) | 2009-05-01 |
| CN101056890A (zh) | 2007-10-17 |
| KR20070084559A (ko) | 2007-08-24 |
| EP1809662B1 (en) | 2008-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60042122D1 (de) | Fibroblasten wachstumsfaktor-ähnliche polypeptide | |
| NO2017028I2 (no) | eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
| BRPI0514790A (pt) | muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano | |
| DK1668031T3 (da) | Homogene præparater af IL-29 | |
| NZ754961A (en) | Growth differentiation factor 15 (gdf-15) constructs | |
| BRPI0416683A (pt) | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 | |
| DK1317537T3 (da) | Sammensætninger og fremgangsmåder med G-CSF analoger | |
| ATE417595T1 (de) | Keratin-bindende polypeptide | |
| DE68929043D1 (de) | Für androgen-rezeptor-protein kodierende dna | |
| EP1773867A4 (en) | PROTEIN-type compounds and applications thereof | |
| MX2021007434A (es) | Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica. | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| ATE415421T1 (de) | Deamidiertes interferon-beta | |
| Guo et al. | Molecular cloning and characterization of a novel bovine IFN-ε | |
| Ketscher et al. | ISG15 uncut: Dissecting enzymatic and non-enzymatic functions of USP18 in vivo | |
| MX2009001348A (es) | Interferon-beta recombinante con actividad biologica mejorada. | |
| NZ562436A (en) | Toll-like receptor 14 (TLR14) and use thereof | |
| WO2008041014A3 (en) | Interferon- alpha constructs for use in the treatment of diseases characterised by abnormal cell proliferation such as cancer | |
| MX2009007248A (es) | Peptidos bio-activos cortos para modulacion celular e inmunologica. | |
| ES2088911T3 (es) | Gen de la proteasa i de achromobacter y el producto de este gen. | |
| TW200722104A (en) | Low-toxicity, long-circulating human interferon-α analogs | |
| KR880701073A (ko) | 제조합 dna 기법에 의해 생성된 민악티빈 | |
| ATE475099T1 (de) | Beurteilung der biologischen aktivität von hgf (hepatocyte growth factor) | |
| ATE423200T1 (de) | Neues plexin-polypeptid, dieses codierende dna und verwendung davon | |
| MX2025013582A (es) | Proteina insecticida y uso de la misma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1809662 Country of ref document: EP |